KR20240156409A - 주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태 - Google Patents

주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태 Download PDF

Info

Publication number
KR20240156409A
KR20240156409A KR1020247033176A KR20247033176A KR20240156409A KR 20240156409 A KR20240156409 A KR 20240156409A KR 1020247033176 A KR1020247033176 A KR 1020247033176A KR 20247033176 A KR20247033176 A KR 20247033176A KR 20240156409 A KR20240156409 A KR 20240156409A
Authority
KR
South Korea
Prior art keywords
articaprant
crystalline form
amorphous
anhedonia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033176A
Other languages
English (en)
Korean (ko)
Inventor
필리프 페르난데스
마크 쉬밋
바니나 포포바
아담 사비츠
라마 멜코트
웨인 씨. 드레베츠
스리하리 고팔
데럴 펨버톤
차크라다르 라기셰티
아이바 케직
Original Assignee
얀센 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티칼즈, 인코포레이티드 filed Critical 얀센 파마슈티칼즈, 인코포레이티드
Publication of KR20240156409A publication Critical patent/KR20240156409A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247033176A 2022-03-07 2023-03-06 주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태 Pending KR20240156409A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317475P 2022-03-07 2022-03-07
US63/317,475 2022-03-07
PCT/IB2023/052088 WO2023170550A1 (en) 2022-03-07 2023-03-06 Polymorph forms of aticaprant for use in treating major depressive disorder

Publications (1)

Publication Number Publication Date
KR20240156409A true KR20240156409A (ko) 2024-10-29

Family

ID=85706849

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033176A Pending KR20240156409A (ko) 2022-03-07 2023-03-06 주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태

Country Status (14)

Country Link
US (3) US11998524B2 (https=)
EP (1) EP4489747A1 (https=)
JP (1) JP2025508051A (https=)
KR (1) KR20240156409A (https=)
CN (1) CN119156211A (https=)
AU (1) AU2023232536A1 (https=)
CA (1) CA3254365A1 (https=)
CL (1) CL2024002627A1 (https=)
CO (1) CO2024012158A2 (https=)
IL (1) IL315409A (https=)
JO (1) JOP20240197A1 (https=)
MX (1) MX2024010980A (https=)
TW (1) TW202345796A (https=)
WO (1) WO2023170550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
WO2000069858A1 (en) 1999-05-12 2000-11-23 F. Hoffmann-La Roche Ag Imidazodiazepine derivative
JP2004510789A (ja) 2000-10-05 2004-04-08 モーラー，ハンス 選択的抗不安治療薬
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
US7396943B2 (en) 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
CN1756746A (zh) 2003-03-07 2006-04-05 伊莱利利公司 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
BRPI0417156A (pt) 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1730140B1 (en) 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
EP1727788B1 (en) 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
CA2557794A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
JP2007529523A (ja) 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
WO2009094260A1 (en) 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
BR112013002846A2 (pt) 2010-08-05 2016-06-07 Conrig Pharma Aps derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
EP2773352B1 (en) 2011-12-09 2017-06-28 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
MX368870B (es) 2013-12-20 2019-10-21 H Lundbeck As Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
US10377698B2 (en) 2015-03-30 2019-08-13 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
US10709685B2 (en) 2015-05-28 2020-07-14 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
WO2017218518A1 (en) 2016-06-13 2017-12-21 Board Of Regents Of The University Of Texas System Pharmaceutical compositions and methods for treatment of pain
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
JP7048572B6 (ja) 2016-09-16 2023-12-20 リサーチ トライアングル インスティテュート テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
ES2926533T3 (es) 2017-03-17 2022-10-26 Scripps Research Inst Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
WO2019183556A1 (en) 2018-03-23 2019-09-26 University Of Kansas Cyclic tetrapeptide analogs
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
JP2022505676A (ja) 2018-10-23 2022-01-14 ブラックソーン セラピューティクス インコーポレイテッド 患者のスクリーニング、診断、及び層別化のためのシステム及び方法
US20200171025A1 (en) 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) * 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2022268720A1 (en) 2021-05-04 2023-12-21 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170547A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant

Also Published As

Publication number Publication date
US20250325515A1 (en) 2025-10-23
US20230277499A1 (en) 2023-09-07
CO2024012158A2 (es) 2024-09-30
US11998524B2 (en) 2024-06-04
JOP20240197A1 (ar) 2024-09-05
CL2024002627A1 (es) 2025-01-24
IL315409A (en) 2024-11-01
CN119156211A (zh) 2024-12-17
MX2024010980A (es) 2024-12-06
JP2025508051A (ja) 2025-03-21
TW202345796A (zh) 2023-12-01
US20240316003A1 (en) 2024-09-26
CA3254365A1 (en) 2023-09-14
AU2023232536A1 (en) 2024-10-24
US12171743B2 (en) 2024-12-24
WO2023170550A1 (en) 2023-09-14
EP4489747A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
Zolkowska et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil
TWI727949B (zh) 調節蛋白質激酶之化合物的固態形式
JP2024535380A (ja) Ｅｇｆｒ阻害剤の多形形態
US20250325515A1 (en) Forms Of Aticaprant
CN117771252A (zh) 神经活性甾类及其使用方法
KR20240158951A (ko) 결정질 아티카프란트의 순수한 형태
KR102772889B1 (ko) (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도
JP2011516430A (ja) ルビプロストン結晶、その製造方法および用途
JP2020502248A (ja) Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物
Budiman SOLID DOSAGE FORM DEVELOPMENT OF GLIBENCLAMIDE-ASPARTAME COCRYSTAL USING THE SOLVENT EVAPORATION METHOD TO INCREASE THE SOLUBILITY OF GLIBENCLAMIDE Original Article
JP2021152077A (ja) テトラヒドロ−ｎ，ｎ−ジメチル−２，２−ジフェニル−３−フランメタンアミン（ａｎａｖｅｘ２−７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
WO2023107966A1 (en) Salt and solid forms of lysergic acid diethylamide (lsd) and analogs
KR20240152410A (ko) 아티카프란트를 포함하는 조성물
KR20180014830A (ko) 결정성 화합물
TWI540131B (zh) 阿瑞吡坦（ａｐｒｅｐｉｔａｎｔ）ｌ－脯胺酸組成物及共晶體
CN116514797A (zh) 美托哌丙嗪的新型多晶型形式
JP2021073171A (ja) （ｒ）−ジミラセタム（１）と（ｓ）−ジミラセタム（２）を非ラセミ比で含む相乗的組成物
CN105829323B (zh) Gdc-0032的多晶型物、其制备方法和药物用途
US12171758B1 (en) Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
CN109790180A (zh) 毒蕈碱乙酰胆碱受体激动剂的结晶多晶型物
Herma et al. Preparation and characterization of novel mirabegron salts for sustaining dissolution and improving diffusion/permeability
EA053068B1 (ru) Полиморфные формы атикапранта для применения при лечении большого депрессивного расстройства
JP2024527992A (ja) 神経刺激性ステロイドの結晶形
WO2024026337A1 (en) Crystalline forms of a neuroactive steroid
BR122024022339A2 (pt) Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol- 4-il)pentanamida, seus usos e composições das mesmas

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000